Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). (Q44674292)

5 December 2017

title

Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). (English)

1 reference

5 December 2017

0 references

7

1 reference

5 December 2017

17

1 reference

Marry M. van den Heuvel-Eibrink

5 December 2017

19

object named as

Marry M van den Heuvel-Eibrink

1 reference

5 December 2017

2

Eva Hoster

1 reference

5 December 2017

20

Dirk Reinhardt

1 reference

5 December 2017

16

Ursula Creutzig

1 reference

5 December 2017

Christian Michel Zwaan

18

object named as

Michel C Zwaan

1 reference

5 December 2017

Friederike Schneider

1

1 reference

5 December 2017

Stephanie Schneider

3

1 reference

5 December 2017

Annika Dufour

4

1 reference

5 December 2017

Tobias Benthaus

5

1 reference

5 December 2017

Purvi M Kakadia

6

1 reference

5 December 2017

Jan Braess

8

1 reference

5 December 2017

Achim Heinecke

9

1 reference

5 December 2017

Maria C Sauerland

10

1 reference

5 December 2017

Wolfgang E Berdel

11

1 reference

5 December 2017

Thomas Buechner

12

1 reference

5 December 2017

Bernhard J Woermann

13

1 reference

5 December 2017

Michaela Feuring-Buske

14

1 reference

5 December 2017

Christian Buske

15

1 reference

5 December 2017

Wolfgang Hiddemann

21

1 reference

5 December 2017

Karsten Spiekermann

22

1 reference

5 December 2017

publication date

9 July 2011

1 reference

5 December 2017

1 reference

5 December 2017

volume

91

1 reference

5 December 2017

issue

1

1 reference

5 December 2017

page(s)

9-18

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1280-6

5 December 2017

1 reference

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1280-6

Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1280-6

Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1280-6

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1280-6

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1280-6

Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1280-6

Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1280-6

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1280-6

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1280-6

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1280-6

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1280-6

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1280-6

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1280-6

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1280-6

DNMT3A Mutations in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1280-6

RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1280-6

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1280-6

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1280-6

NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1280-6

10.1007/S00277-011-1280-6

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference